Nivestim
Hodgkin'S Lymphoma, Mixed Cellularity
Explore 8 assets in Hodgkin'S Lymphoma, Mixed Cellularity →Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03907488CT.gov Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT00302003CT.gov Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00025259CT.gov Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hodgkin'S Lymphoma, Mixed Cellularity
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivestim (this asset) | National Cancer Institute (NCI) | P3 | BB · 69 |
| Etoposide | Northwestern University | P3 | BB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Isocyclophosphamide | Northwestern University | P3 | BB |
| Bleomycin | City of Hope Medical Center | P3 | BB |
| Vinorelbine Ditartrate | National Cancer Institute (NCI) | P3 | BB |
| Dacarbazine | National Cancer Institute (NCI) | P3 | BB |
| Cytarabine | Children's Oncology Group | P3 | BB |
| Dexasone | Children's Oncology Group | P3 | BB |
+21 more in the Hodgkin'S Lymphoma, Mixed Cellularity cohort
Other indications for Nivestim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P4 | BBB · 78 |
| Neutropenia | — | P4 | BBB · 76 |
| Mycosis Fungoides | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivestim in Hodgkin'S Lymphoma, Mixed Cellularity. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/n-met-g-csf-hodgkins-lymphoma-mixed-cellularity
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →